The Pathogenesis and Treatment of Kidney Stones

New England Journal of Medicine

Volumn 327, Issue 16, 1992, Pages 1141-1152

  Coe, Fredric L ^a   Parks, Joan H ^a   Asplin, John R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALI; CALCITRIOL; CALCIUM PHOSPHATE; CELLULOSE PHOSPHATE; CITRIC ACID; CYSTINE; PENICILLAMINE; PHOSPHATE; STRUVITE; THIAZIDE DIURETIC AGENT; TIOPRONIN; URIC ACID;

BONE DENSITY; CALCIUM BALANCE; CLINICAL FEATURE; DIET; DRUG EFFECT; EXTRACORPOREAL LITHOTRIPSY; HUMAN; HYPERCALCIURIA; HYPEROXALURIA; HYPERURICOSURIA; KIDNEY TUBULE ACIDOSIS; NEPHROLITHIASIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STONE ANALYSIS; ULTRASONIC LITHOTRIPSY; URETEROSCOPY; URIC ACID STONE;

EID: 0026760992     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199210153271607     Document Type: Review

References (155)

1. Clinical approach. In: Coe FL, Parks JH. Nephrolithiasis: pathogenesis and treatment. 2nd ed. Chicago: Year Book Medical, 1988:1–37.
2. Millman S, Strauss AL, Parks JH, Coe FL. Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis. Kidney Int 1982; 22: 366–70.
3. Coe FL, Parks JH. Nephrolithiasis: pathogenesis and treatment. 2nd ed. Chicago: Year Book Medical, 1988.
4. Herring LC. Observations on the analysis of ten thousand urinary calculi. J Urol 1962; 88: 545–62.
5. Otnes B. Urinary stone analysis methods, materials and value. Scand J Urol Nephrol Suppl 1983; 71: 1–109.
6. Brand E, Harris MM, Biloon S. Cystinuria: the excretion of a cystine complex which decomposes in the urine with the liberation of free cystine. J Biol Chem 1930; 86: 315–31.
7. Physical chemistry of calcium stone disease. In: Coe FL, Parks JH. Nephrolithiasis: pathogenesis and treatment. 2nd ed. Chicago: Year Book Medical, 1988:38–58.
8. Brown CM, Purich DL. Physical-chemical processes in kidney stone formation. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:613–24.
9. Coe FL, Parks JH, Nakagawa Y. Inhibitors and promoters of calcium oxalate crystallization: their relationship to the pathogenesis and treatment of nephrolithiasis. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:757–800.
10. Uric acid and calcium oxalate stones. In: Coe FL, Parks JH. Nephrolithiasis: pathogenesis and treatment. 2nd ed. Chicago: Year Book Medical, 1988:205–31.
11. Pak CYC, Barilla DE, Holt K, Brinkley L, Tolentino R, Zerwekh JE. Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis. Am J Med 1978; 65: 593–9.
12. Andres A, Praga M, Bello I, et al. Hematuria due to hypercalciuria and hyperuricosuria in adult patients. Kidney Int 1989; 36: 96–9.
13. Kok DJ, Papapoulos SE, Bijvoet OLM. Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 1990; 37: 51–6.
14. Emmerson BT, Cross M, Osborne JM, Axelsen RA. Reaction of MDCK cells to crystals of monosodium urate monohydrate and uric acid. Kidney Int 1990; 37: 36–43.
15. Riese RJ, Riese JW, Kleinman JG. Wiessner JH. Mandel GS. Mandel NS. Specificity in calcium oxalate adherence to papillary epithelial cells in cultures. Am J Physiol 1988; 255: F1025–F1032.
16. Nakagawa Y, Abram V, Parks JH, Lau HS-H, Kawooya JK, Coe FL. Urine glycoprotein crystal growth inhibitors: evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest 1985; 76: 1455–62.
17. Nakagawa Y, Ahmed M, Hall SL, Deganello S, Coe FL. Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth: evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in γ-carboxyglutamic acid. J Clin Invest 1987; 79: 1782–7.
18. Worcester EM, Nakagawa Y, Wabner CL, Kumar S. Coe FL. Crystal absorption and growth slowing by nephrocalcin. albumin, and Tamm-Horsfall protein. Am J Physiol 1988; 255: F1197–F1205.
19. Asplin J, DeGanello S, Nakagawa YN, Coe FL. Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol 1991; 261: F824–F830.
20. Hess B, Nakagawa Y, Parks JH, Coe FL. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 1991; 260: F569–F578.
21. Shiraga H, Min W. VanDusen WJ, et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acidrich protein superfamily. Proc Natl Acad Sci U S A 1992; 89: 426–30.
22. Bretland PM. Acute ureteric obstruction. London: Appleton-Century-Crofts, 1972:1–219.
23. Parks JH, Coe FL, Strauss AL. Calcium nephrolithiasis and medullary sponge kidney in women. N Engl J Med 1982; 306: 1088–91.
24. Consensus Conference. Prevention and treatment of kidney stones. JAMA 1988; 260: 977–81.
25. Blute ML, Segura JW, Patterson DE. Ureteroscopy. J Urol 1988; 139: 510–2.
26. Segura JW. The role of percutaneous surgery in renal and ureteral stone removal. J Urol 1989; 141: 780–1.
27. Lingeman JE. Mechanisms of stone disruption and dissolution. In:Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:625–70.
28. Lingeman JE, Woods J, Toth PD, Evan AP, McAteer JA. The role of lithotripsy and its side effects. J Urol 1989; 141: 793–7.
29. Dabbagh S, Chesney R, Gusowski N, et al. Aminoaciduria of vitamin D deficiency is independent of PTH levels and urinary cyclic AMP. Miner Electrolyte Metab 1989; 15: 221–32.
30. Sutherland JW, Parks JH, Coe FL. Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab 1985; 11: 267–9.
31. Favus MJ. Intestinal absorption of calcium, magnesium, and phosphorus. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:57–82.
32. Yanagawa N, Lee DBN. Renal handling of calcium and phosphorus. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:3–40.
33. Coe FL, Bushinsky DA. Pathophysiology of hypercalciuria. Am J Physiol 1984; 247: F1–F13.
34. Parks J, Coe F, Favus M. Hyperparathyroidism in nephrolithiasis. Arch Intern Med 1980; 140: 1479–81.
35. Primary hyperparathyroidism. In: Coe FL, Parks JH. Nephrolithiasis: pathogenesis and treatment. 2nd ed. Chicago: Year Book Medical, 1988:59–107.
36. Pak CYC. Effect of parathyroidectomy on crystallization of calcium salts in urine of patients with primary hyperparathyroidism. Invest Urol 1979; 17: 146–8.
37. Portale AA, Halloran BP, Morris RC Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989; 83: 1494–9.
38. Ladenson JH. Calcium determination in primary hyperparathyroidism. J Bone Miner Res 1991; 6: Suppl 2: S33–S41.
39. Gardin JP, Paillard M. Normocalcemic primary hyperparathyroidism: resistance to PTH effect on tubular reabsorption of calcium. Miner Electrolyte Metab 1984; 10: 301–8.
40. DeSimone DP, Bell NH. Hypercalcemia and abnormal vitamin D metabolism. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:563–70.
41. Law WM Jr, Heath H III. Familial benign hypercalcemia (hypocalciuric hypercalcemia): clinical and pathogenetic studies in 21 families. Ann Intern Med 1985; 102: 511–9.
42. Marx SJ, Fraser D, Rapoport A. Familial hypocalciuric hypercalcemia: mild expression of the gene in heterozygotes and severe expression in homozygotes. Am J Med 1985; 78: 15–22.
43. Shen F-H, Sherrard DJ. Lithium-induced hyperparathyroidism: an alteration of the “Set-Point.” Ann Intern Med 1982; 96: 63–5.
44. Consensus Development Conference Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference statement. Ann Intern Med 1991; 114: 593–7.
45. Halabe A, Sutton RAL. Primary hyperparathyroidism as a cause of calcium nephrolithiasis. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:671–84.
46. Benson L, Ljunghall S, Åkerström G, Öberg K. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. Am J Med 1987; 82: 731–7.
47. Parks JH, Coe FL. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 1986; 30: 85–90.
48. Coe FL, Parks JH, Moore ES. Familial idiopathic hypercalciuria. N Engl J Med 1979; 300: 337–40.
49. Mehes K, Szelid ZS. Autosomal dominant inheritance of hypercalciuria. Eur J Pediatr 1980; 133: 239–42.
50. Caruana RJ, Buckalew VM Jr. The syndrome of distal (type 1) renal tubular acidosis: clinical and laboratory findings in 58 cases. Medicine (Baltimore) 1988; 67: 84–99.
51. Bianchi G, Vezzoli G, Cusi D, et al. Abnormal red-cell calcium pump in patients with idiopathic hypercalciuria. N Engl J Med 1988; 319: 897–901.
52. Tieder M, Modai D, Shaked U, et al. “Idiopathic” hypercalciuria and hereditary hypophosphatemic rickets: two phenotypical expressions of a common genetic defect. N Engl J Med 1987; 316: 125–9.
53. Tieder M, Modai D, Samuel R, et al. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 1985; 312: 611–7.
54. Tieder M, Arie R, Modai D, Samuel R, Weissgarten J, Liberman UA. Elevated serum 1,25-dihydroxyvitamin D concentrations in siblings with primary Fanconi's syndrome. N Engl J Med 1988; 319: 845–9.
55. Sperling O, Weinberger A, Oliver I, Liberman UA, De Vries A. Hypouricemia, hypercalciuria. and decreased bone density: a hereditary syndrome. Ann Intern Med 1974; 80: 482–7.
56. Mallette LE, Mechanick JI. Heritable syndrome of pseudoxanthoma elasticum with abnormal phosphorus and vitamin D metabolism. Am J Med 1987; 83: 1157–62.
57. Katz SM, Krueger LJ, Falkner B. Microscopic nephrocalcinosis in cystic fibrosis. N Engl J Med 1988; 319: 263–6.
58. Bushinsky DA, Favus MJ. Mechanism of hypercalciuria in genetic hypercalciuric rats: inherited defect in intestinal calcium transport. J Clin Invest 1988; 82: 1585–91.
59. Coe FL, Favus MJ. Disorders of stone formation. In: Brenner BM, Rector FC Jr, eds. The kidney. 3rd ed. Philadelphia: W.B. Saunders, 1986:1403–42.
60. Lemann J Jr. Pathogenesis of idiopathic hypercalciuria and nephrolithiasis. In: Coe FL. Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:685–706.
61. Coe FL, Favus MJ, Crockett T, et al. Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1.25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 1982; 72: 25–32.
62. Pak CYC, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis: classification, clinical presentation and diagnostic criteria. Am J Med 1980; 69: 19–30.
63. Pak CYC, Peters P, Hurt G, et al. Is selective therapy of recurrent nephrolithiasis possible? Am J Med 1981; 71: 615–22.
64. Coe FL, Canterbury JM. Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest 1973; 52: 134–42.
65. Pacifici R, Filipponi P, Mannarelli C, et al. Classification of idiopathic hypercalciuric patients by isotopic calcium absorption: a comparison with oral calcium tolerance test. Calcif Tissue Int 1985; 37: 467–73.
66. Lawoyin S, Sismilich S, Browne R, Pak CYC. Bone mineral content in patients with calcium urolithiasis. Metabolism 1979; 28: 1250–4.
67. Malluche HH, Tschoepe W, Ritz E, Meyer-Sabellek W. Massry SG. Abnormal bone histology in idiopathic hypercalciuria. J Clin Endocrinol Metab 1980; 50: 654–8.
68. Barkin J, Wilson DR, Manuel MA, Bayley A, Murray T, Harrison J. Bone mineral content in idiopathic calcium nephrolithiasis. Miner Electrolyte Metab 1985; 11: 19–24.
69. Bataille P, Achard JM, Fournier A. et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39: 1193–205.
70. Adams ND, Gray RW, Lemann J Jr. The effects of oral CaCO3, loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin D concentrations in healthy adults. J Clin Endocrinol Metab 1979; 48: 1008–16.
71. Maierhofer WJ, Lemann J Jr, Gray RW, Cheung HS. Dietary calcium and scrum l,25-(OH)2-vitamin D concentrations as determinants of calcium balance in healthy men. Kidney Int 1984; 26: 752–9.
72. Brown AJ, Ritter CR, Finch JL, et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728–32.
73. Broadus AE, Insogna KL, Lang R, Ellison AF, Dreyer BE. Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med 1984; 311: 73–80.
74. Kaplan RA, Haussler MR, Deftos LJ, Bone H, Pak CYC. The role of 1α,25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 1977; 59: 756–60.
75. Shen FH, Baylink DJ, Nielsen RL, Sherrard DJ, Ivey JL, Haussler MR. Increased serum 1,25-dihydroxyvitamin D in idiopathic hypercalciuria. J Lab Clin Med 1977; 90: 955–62.
76. Gray RW, Wilz DR, Caldas AE, Lemann J Jr. The importance of phosphate in regulating plasma 1,25-(OH)2-vitamin D levels in humans: studies in healthy subjects, in calcium-stone formers and in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 1977; 45: 299–306.
77. Coe FL, Parks JH, Bushinsky DA, Langman CB, Favus MJ. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int 1988; 33: 1140–6.
78. Shimizu T, Nakamura M, Yoshitomi K, Imai M. Interaction of trichlormethiazide oramiloride with PTH in stimulating Ca2+ absorption in rabbit CNT. Am J Physiol 1991; 261: F36–F43.
79. LaCroix AZ, Wienpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990; 322: 286–90.
80. Wasnich RD, Benfante RJ, Yano K, Heilbrun L, Vogel JM. Thiazide effect on the mineral content of bone. N Engl J Med 1983; 309: 344–7.
81. Heidrich FE, Stergachis A, Gross KM. Diuretic drug use and risk for hip fracture. Ann Intern Med 1991; 115: 1–6.
82. Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988; 139: 679–84.
83. Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis: a double-blind study in general practice. Acta Med Scand 1984; 215: 383–9.
84. Smith LH, Thomas WC Jr, Arnaud CD. Orthophosphate therapy in calcium renal lithiasis. In: Urinary calculi: proceedings of the International Symposium on Renal Stone Research, Madrid, 1972. Basel, Switzerland: Karger. 1973:188–97.
85. Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 1983; 130: 1115–8.
86. Wilson DR, Strauss AL, Manuel MA. Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. Urol Res 1984; 12: 39–40. abstract.
87. Backman U, Danielson BG, Johansson G, Ljunghall S, Wikström B. Treatment of recurrent calcium stone formation with cellulose phosphate. J Urol 1980; 123: 9–13.
88. Pak CYC, Fuller C. Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate. Ann Intern Med 1986; 104: 33–7.
89. Smith LH. Hyperoxaluric states. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:707–28.
90. Andersson H, Jagenburg R. Fat-reduced diet in the treatment of hyperoxaluria in patients with ileopathy. Gut 1974; 15: 360–6.
91. Scheinman JI. Primary hyperoxaluria: therapeutic strategies for the 90's. Kidney Int 1991; 40: 389–99.
92. Yendt ER, Cohanim M. Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria. N Engl J Med 1985; 312: 953–7.
93. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986; 315: 1386–9
94. Geeson MJ, Kobashi K, Griffith DP. Noncalcium nephrolithiasis. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press. 1992:801–29.
95. Williams JJ, Rodman JS. Peterson CM. A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. N Engl J Med 1984; 311: 760–4.
96. Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 1982; 128: 903–7.
97. Brocks P, Dahl C, Wolf H, Transbøl I. Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet 1981; 2: 124–5.
98. Segal S. Thier SO. Cystinuria. In: Stanbury JB, Wyngaarden JB. Fredrickson DS, Goldstein JL, Brown MS, eds. The metabolic basis of inherited disease. 5th ed. New York: McGraw-Hill, 1983:1774–91.
99. Cystine stones. In: Coe FL, Parks JH. Nephrolithiasis: pathogenesis and treatment. 2nd ed. Chicago: Year Book Medical, 1988:269–75.
100. Maschio G, Tessitore N, D'Angelo A. et al. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol. Am J Med 1981; 71: 623–6.
101. Elomaa I, Ala-Opas M, Porkka L. Five years of experience with selective therapy in recurrent calcium nephrolithiasis. J Urol 1984; 132: 656–61.
102. Backman U, Danielson BG, Johansson G, Ljunghall S, Wikström B. Effects of therapy with bendroflumethiazide in patients with recurrent renal calcium stones. Br J Urol 1979; 51: 175–80.
103. Ahlstrand C, Tiselius HG, Larsson L, Hellgren E. Clinical experience with long-term bendroflumcthiazide treatment in calcium oxalate stone formers. Br J Urol 1984; 56: 255–62.
104. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med 1977; 87: 404–10.
105. Pak CYC, Delea CS, Bartter FC. Successful treatment of recurrent nephrolithiasis (calcium stones) with cellulose phosphate. N Engl J Med 1974; 290: 175–80.
106. Blacklock NJ, Macleod MA. The effect of cellulose phosphate on intestinal absorption and urinary excretion of calcium: some experience in its use in the treatment of calcium stone formation. Br J Urol 1974; 46: 385–92.
107. Dent CE, Harper CM. Parfitt AM. The effect of cellulose phosphate on calcium metabolism in patients with hypercalciuria. Clin Sci 1964; 27: 417–25.
108. Hayashi Y, Kaplan RA, Pak CYC. Effect of sodium cellulose phosphate therapy on crystallization of calcium oxalate in urine. Metabolism 1975; 24: 1273–8.
109. Insogna KL, Ellison AS, Burtis WJ, Sartori L, Lang RL, Broadus AE. Trichlormethiazide and oral phosphate therapy in patients with absorptive hypercalciuria. J Urol 1989; 141: 269–74.
110. Ettinger B. Recurrent nephrolithiasis: natural history and effect of phosphate therapy: a double-blind controlled study. Am J Med 1976; 61: 200–6.
111. Nikkila M, Koivula T. Jokela H. Urinary citrate excretion in patients with urolithiasis and normal subjects. Eur Urol 1989; 16: 382–5.
112. Minisola S, Rossi W, Pacitti MT, et al. Studies on citrate metabolism in normal subjects and kidney stone patients. Miner Electrolyte Metab 1989; 15: 303–8.
113. Rudman D, Kutner MH, Redd SC II, Waters WC IV, Gerron GG, Bleier J. Hypocitraturia in calcium nephrolithiasis. J Clin Endocrinol Metab 1982; 55: 1052–7.
114. Hosking DH, Wilson JWL, Liedtke RR, Smith LH, Wilson DM. Urinary citrate excretion in normal persons and patients with idiopathic calcium urolithiasis. J Lab Clin Med 1985; 106: 682–9.
115. Conte A, Roca P, Gianotti M, Grases F. On the relation between citrate and calcium in normal and stone-former subjects. Int Urol Nephrol 1989; 21: 369–73.
116. Pak CYC, Peterson R, Sakhaee K, Fuller C, Preminger G, Reisch J. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. Am J Med 1985; 79: 284–8.
117. Buckalew VM Jr. Calcium nephrolithiasis and renal tubular acidosis. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:729–56.
118. Lemann J Jr, Pleuss JA, Gray RW, Hoffmann RG. Potassium administration increases and potassium deprivation reduces urinary calcium excretion in healthy adults. Kidney Int 1991; 39: 973–83.
119. Lemann J Jr, Gray RW, Pleuss JA. Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men. Kidney Int 1989; 35: 688–95.
120. Calcium phosphate stones and renal tubular acidosis. In: Coe FL, Parks JH. Nephrolithiasis: pathogenesis and treatment. 2nd ed. Chicago: Year Book Medical, 1988:139–71.
121. Coe FL, Parks JH. Stone disease in hereditary distal renal tubular acidosis. Ann Intern Med 1980; 93: 60–1.
122. Gault MH, Chafe LL, Morgan JM, et al. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine (Baltimore) 1991; 70: 345–59.
123. Jaeger P, Portmann L, Jacquet AF. Burckhardt P. influence of the calcium content of the diet on the incidence of mild hyperoxaluria in idiopathic renal stone formers. Am J Nephrol 1985; 5: 40–4.
124. Smith LH, Fromm H, Hofmann AF. Acquired hyperoxaluria, nephrolithiasis, and intestinal disease: description of a syndrome. N Engl J Med 1972; 286: 1371–5.
125. Dowling RH, Rose GA, Sutor DJ. Hyperoxaluria and renal calculi in ileal disease. Lancet 1971; 1: 1103–6.
126. Cryer PE, Garber AJ, Hoffsten P, Lucas B, Wise L. Renal failure after small intestinal bypass for obesity. Arch Intern Med 1975; 135: 1610–2.
127. Vainder M, Kelly J. Renal tubular dysfunction secondary to jejunoileal bypass. JAMA 1976; 235: 1257–8.
128. Dobbins JW, Binder HJ. Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology 1976; 70: 1096–100.
129. Kathpalia SC, Favus MJ, Coe FL. Evidence for size and charge permselectivity of rat ascending colon: effects of ricinoleate and bile salts on oxalic acid and neutral sugar transport. J Clin Invest 1984; 74: 805–11.
130. Halverson JD, Wise L, Wazna MF, Ballinger WF. Jejunoileal bypass for morbid obesity: a critical appraisal. Am J Med 1978; 64: 461–75.
131. Gelbart DR, Brewer LL, Fajardo LF, Weinstein AB. Oxalosis and chronic renal failure after intestinal bypass. Arch Intern Med 1977; 137: 239–43.
132. Drenick EJ, Stanley TM, Border WA, et al. Renal damage with intestinal bypass. Ann Intern Med 1978; 89: 594–9.
133. Wharton R, D'Agati V, Magun AM, Whitlock R, Kunis CL, Appel GB. Acute deterioration of renal function associated with enteric hyperoxaluria. Clin Nephrol 1990; 34: 116–21.
134. Itami N, Yasoshima K, Akutsu Y, Nonomura K. Spot-urine screening for primary hyperoxaluria. Nephron 1990; 56: 337–8.
135. Watts RWE, Morgan SH, Danpure CL, et al. Combined hepatic and renal transplantation in primary hyperoxaluria type I: clinical report of nine cases. Am J Med 1991; 90: 179–88.
136. Worcester EM, Nakagawa Y, Bushinsky DA, Coe FL. Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure. J Clin Invest 1986; 77: 1888–96.
137. Coe FL, Raisen L. Allopurinol treatment of uric-acid disorders in calcium-stone formers. Lancet 1973; 1: 129–31.
138. Finlayson B, Burns J, Smith A, Du Bois L. Effect of oxipurinol and allopurinol riboside on whewellite crystallization: in vitro and in vivo observations. Invest Urol 1979; 17: 227–9.
139. Coe FL, Lawton RL, Goldstein RB, Tembe V. Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc Soc Exp Biol Med 1975; 149: 926–9.
140. Deganello S, Coe FL. Epitaxy between uric acid and whewellite: experimental verification. N Jb Miner Mh 1983; 6: 270–6.
141. Coe FL, Strauss AL, Tembe V, Le Dun S. Uric acid saturation in calcium nephrolithiasis. Kidney Int 1980; 17: 662–8.
142. Zerwekh JE, Holt K, Pak CY. Natural urinary macromolecular inhibitors: attenuation of inhibitory activity by urate salts. Kidney Int 1983; 23: 838–41.
143. Pak CYC, Holt K, Zerwekh JE. Attenuation by monosodium urate of the inhibitory effect of glycosaminoglycans on calcium oxalate nucleation. Invest Urol 1979; 17: 138–40.
144. Pak CYC, Holt K, Britton F, Peterson R, Crowther C, Ward D. Assessment of pathogenetic roles of uric acid, monopotassium urate, monoammonium urate and monosodium urate in hyperuricosuric calcium oxalate nephrolithiasis. Miner Electrolyte Metab 1980; 4: 130–6.
145. Grover PK, Ryall RL, Marshall VR. Effect of urate on calcium oxalate crystallization in human urine: evidence for a promotory role of hyperuricosuria in urolithiasis. Clin Sci 1990; 79: 9–15.
146. Coe FL, Kavalach AG. Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 1974; 291: 1344–50.
147. Coe FL, Moran E, Kavalich AG. The contribution of dietary purine over-consumption to hyperuricosuria in calcium oxalate stone formers. J Chronic Dis 1976; 29: 793–800.
148. Coe FL. Hyperuricosuric calcium oxalate nephrolithiasis. Kidney Int 1978; 13: 418–26.
149. Coe FL, Margolis HC, Deutsch LH, Strauss AL. Urinary macromolecular crystal growth inhibitors in calcium nephrolithiasis. Miner Electrolyte Metab 1980; 3: 268–75.
150. Millman S, Strauss AL, Parks JH, Coe FL. Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis. Kidney Int 1982; 22: 366–70.
151. Sakhaee K, Alpern R, Jacobson HR, Pak CYC. Contrasting effects of various potassium salts on renal citrate excretion. J Clin Endocrinol Metab 1991; 72: 396–400.
152. Preminger GM, Sakhaee K, Pak CY. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol 1988; 139: 240–2.
153. Griffith DP, Bruce RR. Infection (urease)-induced stones. In: Coe FL, Brenner BM, Stein JH, eds. Nephrolithiasis. Vol. 5 of Contemporary issues in nephrology. New York: Churchill Livingstone, 1980:231–60.
154. Kristensen C, Parks JH, Lindheimer M, Coe FL. Reduced glomerular filtration rate and hypercalciuria in primary struvite nephrolithiasis. Kidney Int 1987; 32: 749–53.
155. Martensson J, Denneberg T, Lindell A, Textorius O. Sulfur amino acid metabolism in cystinuria: a biochemical and clinical study of patients. Kidney Int 1990; 37: 143–9.